Global Generics Industry Profile & Value Chain Analysis
Global Generics Industry Profile & Value Chain Analysis
SUMMARY
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
The value chain analysis reveals the business activities which comprise the global generics market value chain. All key stages are highlighted, along with examples of companies active, and assessments of the burning issues for every stage of the value chain. Key value chain stages analyzed include raw ingredients, manufacturing, buyers and end-users.
SYNOPSIS
Essential resource for top-line data and analysis covering the global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
SUMMARY
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
The value chain analysis reveals the business activities which comprise the global generics market value chain. All key stages are highlighted, along with examples of companies active, and assessments of the burning issues for every stage of the value chain. Key value chain stages analyzed include raw ingredients, manufacturing, buyers and end-users.
SYNOPSIS
Essential resource for top-line data and analysis covering the global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.
- Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.
- The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.
- Raw ingredients for generic drugs are often made by the leading pharmaceutical companies. Given the vast number of ingredients used in generics it is not realistically possible for any one company to produce them all.
- Manufacturing is dominated by major international pharmaceutical companies, but specialist generic companies exist in the market, although these are often small in scale.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the global
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume
- Quickly and easily identify the key stages and sub-stages of the global generics market value chain
- See examples of companies active at each stage of the global generics market value chain
- Examine trends and burning issues impacting the global generics market value chain
- What was the size of the global generics market by value in 2016?
- What will be the size of the global generics market in 2021?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?
- Who are the top competitors in the global generics market?
- What are the key stages and sub-stages of the global generics market value chain?
Executive Summary
Value chain analysis
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Value Chain Analysis
Generics Market complete value chain overview
Raw Ingredients
Manufacturing
Buyers
End-Users
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Value chain analysis
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Value Chain Analysis
Generics Market complete value chain overview
Raw Ingredients
Manufacturing
Buyers
End-Users
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: Global generics market value: $ billion, 2012-16
Table 2: Global generics market volume: % of total pharma volume, 2012-16
Table 3: Global generics market geography segmentation: $ billion, 2016
Table 4: Global generics market value forecast: $ billion, 2016-21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sun Pharmaceutical Industries Ltd: key facts
Table 13: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 14: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 15: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 1: Global generics market value: $ billion, 2012-16
Table 2: Global generics market volume: % of total pharma volume, 2012-16
Table 3: Global generics market geography segmentation: $ billion, 2016
Table 4: Global generics market value forecast: $ billion, 2016-21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sun Pharmaceutical Industries Ltd: key facts
Table 13: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 14: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 15: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
LIST OF FIGURES
Figure 1: Generics Market complete value chain overview
Figure 2: Generics Market Sector complete value chain with active companies
Figure 3: Raw Ingredients - Overview
Figure 4: Manufacturing - Overview
Figure 5: Buyers - Overview
Figure 6: End-Users - Overview
Figure 7: Global generics market value: $ billion, 2012-16
Figure 8: Global generics market volume: % of total pharma volume, 2012-16
Figure 9: Global generics market geography segmentation: % share, by value, 2016
Figure 10: Global generics market value forecast: $ billion, 2016-21
Figure 11: Global generics market volume forecast: % of total pharma volume, 2016-21
Figure 12: Forces driving competition in the global generics market, 2016
Figure 13: Drivers of buyer power in the global generics market, 2016
Figure 14: Drivers of supplier power in the global generics market, 2016
Figure 15: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 16: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 17: Drivers of degree of rivalry in the global generics market, 2016
Figure 18: Mylan N.V.: revenues & profitability
Figure 19: Mylan N.V.: assets & liabilities
Figure 20: Novartis AG: revenues & profitability
Figure 21: Novartis AG: assets & liabilities
Figure 22: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 23: Sun Pharmaceutical Industries Ltd: assets & liabilities
Figure 24: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 25: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 1: Generics Market complete value chain overview
Figure 2: Generics Market Sector complete value chain with active companies
Figure 3: Raw Ingredients - Overview
Figure 4: Manufacturing - Overview
Figure 5: Buyers - Overview
Figure 6: End-Users - Overview
Figure 7: Global generics market value: $ billion, 2012-16
Figure 8: Global generics market volume: % of total pharma volume, 2012-16
Figure 9: Global generics market geography segmentation: % share, by value, 2016
Figure 10: Global generics market value forecast: $ billion, 2016-21
Figure 11: Global generics market volume forecast: % of total pharma volume, 2016-21
Figure 12: Forces driving competition in the global generics market, 2016
Figure 13: Drivers of buyer power in the global generics market, 2016
Figure 14: Drivers of supplier power in the global generics market, 2016
Figure 15: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 16: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 17: Drivers of degree of rivalry in the global generics market, 2016
Figure 18: Mylan N.V.: revenues & profitability
Figure 19: Mylan N.V.: assets & liabilities
Figure 20: Novartis AG: revenues & profitability
Figure 21: Novartis AG: assets & liabilities
Figure 22: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 23: Sun Pharmaceutical Industries Ltd: assets & liabilities
Figure 24: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 25: Teva Pharmaceutical Industries Limited: assets & liabilities
